Pharmaceuticals Buyers & Acquisitions in Illinois

Tracked deals

6

6 tracked deals across 2021-2025.

Buyer mix

Strategic-led

5 strategic · 1 pe

Top trend

Volume peaked in 2024

3 tracked deals announced in 2024.

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Pharmaceuticals deal →
Buyer # Deals Focus Type
AbbVie 1 Global biopharmaceutical company focused on developing an... Strategic
AbbVie Inc. 1 Global biopharmaceutical company focused on developing an... Strategic
ESTEVE (Esteve CDMO / Esteve Química) 1 Global pharmaceutical company and CDMO specializing in sm... Strategic
Formosa Laboratories, Inc. 1 Taiwan-based API supplier and contract development/manufa... Strategic
Grünenthal 1 Science-based, fully integrated pharmaceutical company sp... Strategic
SK Capital Partners 1 Private investment firm focused on specialty materials, c... PE

Acquisition Volume in Pharmaceuticals in Illinois by Year

Last 4 years

Acquisition volume by year Annual acquisition counts for the last 4 years for Pharmaceuticals Buyers & Acquisitions in Illinois. 1 2021 1 2023 3 2024 1 2025

Supporting Data

Recent Transactions

  • ESTEVE Acquires Regis Technologies
    July 31, 2025
    Buyer
    ESTEVE (Esteve CDMO / Esteve Química)
    Target
    Regis Technologies, Inc.
    Industry
    Pharmaceuticals
    Location
    Illinois, United States
    Type
    Buyout

    ESTEVE (Esteve Química / ESTEVE CDMO) has acquired Regis Technologies, a Chicago-based contract development and manufacturing organization (CDMO) specializing in small-molecule APIs and separation products. The acquisition gives ESTEVE a physical U.S. presence, expands its early-stage development and cGMP API manufacturing capabilities, and adds ~70 employees to its US team.

  • Grünenthal Acquires Valinor Pharma for Approximately $250M
    July 22, 2024
    Buyer
    Grünenthal
    Target
    Valinor Pharma
    Seller
    Valinor Pharma
    Industry
    Pharmaceuticals
    Location
    Illinois, United States
    Type
    Buyout

    Grünenthal has acquired Chicago-based Valinor Pharma, including global rights to Movantik (naloxegol), in a transaction valued at about $250 million. The deal strengthens Grünenthal's U.S. footprint and adds an established pain-management product to its portfolio after Valinor scaled Movantik sales using Apollo Care's commercial and patient-access solutions.

  • Formosa Laboratories Acquires SynChem to Expand North American CDMO Footprint
    June 3, 2024
    Buyer
    Formosa Laboratories, Inc.
    Target
    SynChem, Inc.
    Industry
    Pharmaceuticals
    Location
    Illinois, United States
    Type
    Buyout

    Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.

  • AbbVie Completes Acquisition of Landos Biopharma
    May 23, 2024
    Buyer
    AbbVie
    Target
    Landos Biopharma, Inc.
    Industry
    Pharmaceuticals
    Location
    Illinois, United States
    Type
    Buyout

    AbbVie completed its acquisition of clinical-stage biopharmaceutical company Landos Biopharma for $20.42 per share in cash, plus a contingent value right (CVR) tied to a clinical milestone. The deal adds Landos’ first-in-class investigational asset NX-13 to AbbVie’s immunology pipeline for potential treatment of ulcerative colitis and Crohn’s disease.

  • AbbVie to Acquire ImmunoGen for $10.1 Billion
    November 30, 2023
    Buyer
    AbbVie Inc.
    Target
    ImmunoGen, Inc.
    Industry
    Pharmaceuticals
    Location
    Illinois, United States
    Type
    Buyout

    AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.

  • SK Capital Acquires Catalent's Blow‑Fill‑Seal Sterile CDMO Business (Woodstock Sterile Solutions)
    March 31, 2021
    Buyer
    SK Capital Partners
    Target
    Woodstock Sterile Solutions
    Seller
    Catalent Pharma Solutions
    Industry
    Pharmaceuticals
    Location
    Illinois, United States
    Type
    Divestiture

    Funds managed by SK Capital Partners completed the acquisition of Catalent Pharma Solutions' Blow‑Fill‑Seal (BFS) sterile CDMO business and relaunched the business as Woodstock Sterile Solutions. The single‑site Woodstock, Illinois operation will operate independently under new CEO Paul Josephs, supporting global pharmaceutical and biologics customers; Catalent was the seller and debt financing was provided by Cerberus Business Finance.

Build a buyer list for your Pharmaceuticals deal

Find buyers actively acquiring pharmaceuticals companies.

Apply as a Buyer

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions Pharmaceuticals Buyers & Acquisitions in Canada Private Equity-Backed Pharmaceuticals Buyers Pharmaceuticals Acquisitions in 2025 Pharmaceuticals Acquisitions in 2024 Pharmaceuticals Acquisitions in 2023 Pharmaceuticals Acquisitions in 2021 Acquisitions in Illinois Private Equity-Backed Acquisitions in Illinois Acquisitions in Illinois in 2025 Acquisitions in Illinois in 2024 Acquisitions in Illinois in 2023